Drug intelligence / Profile preview

doxycycline + s-equol

Development stage
Unknown
Lead developer
Otsuka Holdings
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Doxycycline + s-equol is a combination of two agents with distinct mechanisms and uses. Doxycycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit in bacteria. It is used to treat a wide range of bacterial infections including respiratory tract infections, sexually transmitted infections such as chlamydia and gonorrhea, acne, rosacea, urinary tract infections, and for malaria prophylaxis[1][2][5]. S-equol is a nonsteroidal estrogen produced from soy isoflavones by intestinal bacteria or synthesized directly; it acts as an agonist with selective affinity for estrogen receptor beta (ERβ), functioning as a selective estrogen receptor modulator[6]. S-equol has been investigated for its potential benefits in hormone-dependent conditions such as menopausal symptoms and breast cancer[6][8].

Other names
doxycycline hyclatedoxycycline monohydrateequol
02

Targets

Bacterial RibosomeESR2 (ERβ)

Beyond the preview

Go deeper on doxycycline + s-equol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxycycline + s-equol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call